The stock of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) is a huge mover today! About 560,355 shares traded hands or 62.11% up from the average. AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) has risen 14.04% since March 15, 2016 and is uptrending. It has outperformed by 8.56% the S&P500.
The move comes after 9 months positive chart setup for the $45.62M company. It was reported on Oct, 18 by Barchart.com. We have $7.40 PT which if reached, will make NASDAQ:AEZS worth $33.76 million more.
Analysts await AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) to report earnings on November, 3. They expect $-0.74 EPS, up 89.43% or $6.26 from last year’s $-7 per share. After $-0.71 actual EPS reported by AEterna Zentaris Inc. (USA) for the previous quarter, Wall Street now forecasts 4.23% negative EPS growth.
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) Ratings Coverage
Out of 3 analysts covering Aeterna Zentaris Inc. (NASDAQ:AEZS), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Aeterna Zentaris Inc. has been the topic of 5 analyst reports since August 18, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Canaccord Genuity given on Monday, November 9. The rating was maintained by H.C. Wainwright on Tuesday, November 24 with “Buy”. H.C. Wainwright maintained it with “Buy” rating and $12.0 target price in Wednesday, December 2 report. The firm earned “Buy” rating on Monday, November 23 by Maxim Group.
According to Zacks Investment Research, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers.”
AEZS Company Profile
Aeterna Zentaris Inc., incorporated on October 12, 1990, is a specialty biopharmaceutical firm engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Firm operates through the biopharmaceutical segment. The Firm is engaged in drug development activities and in the promotion of products for others. The Company’s principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Firm focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company’s direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.